Morgan Stanley Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price reduced by equities research analysts at Morgan Stanley from $755.00 to $754.00 in a research report issued on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s target price suggests a potential upside of 32.81% from the company’s current price.

REGN has been the subject of several other reports. The Goldman Sachs Group dropped their price target on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating for the company in a research report on Wednesday, April 30th. Truist Financial reduced their target price on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating for the company in a research report on Wednesday, April 30th. UBS Group lowered their price target on shares of Regeneron Pharmaceuticals from $633.00 to $560.00 and set a “neutral” rating on the stock in a research report on Thursday, June 5th. JPMorgan Chase & Co. decreased their target price on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating on the stock in a research note on Monday, June 9th. Finally, Royal Bank Of Canada lowered Regeneron Pharmaceuticals from a “moderate buy” rating to a “hold” rating and set a $662.00 price target for the company. in a research report on Friday, May 30th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $823.54.

Regeneron Pharmaceuticals Trading Up 1.4%

Shares of NASDAQ:REGN opened at $567.74 on Thursday. The business’s 50 day moving average price is $545.22 and its 200-day moving average price is $620.50. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $1,211.20. The firm has a market capitalization of $61.29 billion, a price-to-earnings ratio of 14.45, a price-to-earnings-growth ratio of 2.08 and a beta of 0.33. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The company had revenue of $3.03 billion for the quarter, compared to analysts’ expectations of $3.40 billion. During the same period in the prior year, the firm earned $9.55 EPS. The firm’s revenue for the quarter was down 3.7% on a year-over-year basis. On average, equities research analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Brighton Jones LLC grew its position in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after buying an additional 686 shares in the last quarter. Proficio Capital Partners LLC grew its holdings in Regeneron Pharmaceuticals by 30.5% during the 4th quarter. Proficio Capital Partners LLC now owns 308 shares of the biopharmaceutical company’s stock worth $219,000 after acquiring an additional 72 shares in the last quarter. Larson Financial Group LLC grew its holdings in Regeneron Pharmaceuticals by 62.0% during the 4th quarter. Larson Financial Group LLC now owns 81 shares of the biopharmaceutical company’s stock worth $58,000 after acquiring an additional 31 shares in the last quarter. American Assets Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $427,000. Finally, Johnson Investment Counsel Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 73.9% in the 4th quarter. Johnson Investment Counsel Inc. now owns 487 shares of the biopharmaceutical company’s stock valued at $347,000 after purchasing an additional 207 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.